Generic Medicine Info
Active bleeding or increased risk of haemorrhage related to haemostasis disorders (except disseminated intravascular coagulation not heparin-induced); haemorrhagic CVA, organic lesions likely to bleed (e.g. active peptic ulcer), history of thrombocytopenia with nadroparin; acute infectious endocarditis. Severe renal impairment (CrCl <30 mL/min) when used for the treatment of thromboembolic disorders, unstable angina, and non-Q wave MI.
Special Precautions
Patient with severe arterial hypertension, history of gastrointestinal ulceration, vascular disorder of chorio-retina, hepatic failure, risk factors for hyperkalaemia (e.g. diabetes mellitus, metabolic acidosis, haematoma in body tissues, use of ACE inhibitors, NSAIDs, K-sparing diuretics or K supplements). Patients who are undergoing knee surgery, spinal puncture, or receiving neuraxial anaesthesia (spinal or epidural anaesthesia); postoperative period after brain, spinal cord or eye surgery. Not interchangeable (unit for unit) with any other LMWHs or heparin. Not intended for IM administration. Hepatic and moderate renal (CrCl ≥30 to <50 mL/min) impairment. Elderly. Pregnancy and lactation. Monitoring Parameters Monitor platelet count at baseline and twice weekly during treatment; antifactory Xa levels at least 4 hours postdose as clinically indicated; stool occult blood tests, Hb, LFT, renal function; plasma K levels in patients at risk of hyperkalaemia. Closely monitor for signs and symptoms of bleeding, thrombocytopenia with thrombosis and neurological impairment, and clotting in the dialysis circuit (when used during haemodialysis).
Adverse Reactions
Significant: Haemorrhage at any site, thrombocytopenia with thrombosis, heparin-induced thrombocytopenia, hyperkalaemia, prosthetic valve thrombosis; epidural or spinal haematomas including subsequent chronic or permanent paralysis (in patients receiving neuraxial anaesthesia or undergoing spinal puncture). Rarely, cutaneous necrosis (preceded by purpura, infiltrated or painful erythematous blotches). Blood and lymphatic system disorders: Rarely, eosinophilia (reversible). General disorders and administration site conditions: Inj site haematoma and reaction. Immune system disorders: Rarely, hypersensitivity reactions. Investigations: Increased transaminases (transient). Nervous system disorders: Headache, migraine. Reproductive system and breast disorders: Rarely, priapism. Skin and subcutaneous tissue disorders: Rarely, rash, erythema, urticaria, pruritus.
Drug Interactions
Increased risk of bleeding with aspirin, antiplatelet agents and NSAIDs. May enhance the hyperkalaemic effect of ACE inhibitors and K-sparing diuretics.
CIMS Class
Anticoagulants, Antiplatelets & Fibrinolytics (Thrombolytics)
ATC Classification
B01AB06 - nadroparin ; Belongs to the class of heparin group. Used in the treatment of thrombosis.
Disclaimer: This information is independently developed by CIMS based on nadroparin from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2022 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in